Farringdon Capital, Ltd. Bristol Myers Squibb CO Transaction History
Farringdon Capital, Ltd.
- $393 Billion
- Q3 2025
A detailed history of Farringdon Capital, Ltd. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Farringdon Capital, Ltd. holds 14,862 shares of BMY stock, worth $695,690. This represents 0.17% of its overall portfolio holdings.
Number of Shares
14,862
Previous 12,942
14.84%
Holding current value
$695,690
Previous $599 Million
11.88%
% of portfolio
0.17%
Previous 0.2%
Shares
2 transactions
Others Institutions Holding BMY
# of Institutions
2,692Shares Held
1.58BCall Options Held
28MPut Options Held
28.4M-
Vanguard Group Inc Valley Forge, PA196MShares$9.17 Billion0.14% of portfolio
-
Black Rock Inc. New York, NY159MShares$7.43 Billion0.15% of portfolio
-
State Street Corp Boston, MA96.6MShares$4.52 Billion0.16% of portfolio
-
Jpmorgan Chase & CO New York, NY86.2MShares$4.03 Billion0.26% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA73MShares$3.42 Billion0.55% of portfolio
About BRISTOL MYERS SQUIBB CO
- Ticker BMY
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 2,126,160,000
- Market Cap $99.5B
- Description
- Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...